Kelly Doyle, PhD

Assistant Professor, University of Utah School of Medicine

Education

• Doctorate Degree—Medicinal Chemistry, University of Utah
• Fellowship--Clinical Chemistry, University of Utah School of Medicine
• Fellowship—Oncological Sciences, University of Utah, Huntsman Cancer Institute

Certification/Affiliations

• American Board of Clinical Chemistry
• American Association of Clinical Chemistry Academy

Research Interests

• Clinical application and implementation of mass spectrometry
• Emerging biomarkers
• Toxicology
• Endocrinology
• Laboratory best practices

Recent Publications

• Johnson-Davis KL, Doyle K. Therapeutic drug monitoring in pregnant patients. Ther Drug Monit. 2019 Oct 11.
• Bahr TM, et al. Ferritin in serum and urine: a pilot study. Blood Cells Mol Dis. 2019 May;76:59­­­­–62.
• Natali R, et al. Evaluation of a new venous catheter blood draw device and its impact on specimen hemolysis rates. Practical Laboratory Medicine. 2018 Mar;10:38–43.
• Gupta S, et al. Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells. Oncotarget. 2018 Jan 6;9(11):9907–24.
• Doyle K, Strathmann FG. Cost and efficacy assessment of an alternative medication
• compliance urine drug testing strategy. Pain Med. 2017 Feb 1;18(2):307–15.